Scientech Research LLC Intellia Therapeutics, Inc. Call Options Transaction History
Scientech Research LLC
- $485 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NTLA
# of Institutions
318Shares Held
89.3MCall Options Held
668KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.3MShares$204 Million2.39% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$160 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$160 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$79.9 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$72.6 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.27B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...